Rentschler doubles capacity with new manufacturing plant

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Biotechnology

Rentschler doubles capacity with new manufacturing plant
Rentschler Biotechnologie has opened a facility at its site in Laupheim, Germany and plans to create 200 new jobs.

The plant – which cost €24m ($26m) - houses two 3,000 litre stainless steel bioreactors linked to a protein purification system. Clinical-stage protein therapeutics and commercial products will be made at the site.

Rentschler CEO Frank Mathias said: “An increase in sales of over 30% in the past two years has enabled us to make this significant investment. We have already received manufacturing orders for the new facility, extending into 2018​.”

He added that: “Increasingly, our growth is being driven by international business, with more and more orders coming from abroad, particularly the United States​."

Rentschler also said it plans to hire 200 employees, explaining this will include process engineers and laboratory technicians in bioprocess development and manufacturing as well as GMP (Good Manufacturing Practices) experts, as it continues to expand its business.

Expansion

The new facility is the second expansion Rentschler has undertaken in a year. In April​ last year the German contract manufacturing organisation (CMO) installed a single-use bioreactor at its older facility at the Laupheim site.

That expansion coincided with Rentschler being contracted to make Apeiron’s neuroblastoma candidate monoclonal antibody (mAb) APN311​.

A few months later the CMO was hired by Probiodrug​ to makes its Alzheimer’s disease drug candidate PBD-C06, a pGlu-Abeta-specific mAb.

Related news

Show more

Related products

show more

High quality excipients and formulation support

High quality excipients and formulation support

Roquette Pharma Solutions | 09-Nov-2021 | Product Brochure

As the world grapples with the effects of ongoing health crises, the market is expanding quickly as developers shift their focus to proactive therapeutics....

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars